Keyphrases
Multiple Sclerosis Treatment
100%
Anti-CD20 Antibody
100%
Multiple Sclerosis
75%
B Cells
50%
Disease Activity
50%
Infection Risk
25%
Treatment Strategy
25%
Older Adults
25%
Clinical Trials
25%
Disease Progression
25%
Inflammatory Diseases
25%
PubMed
25%
Risk-benefit
25%
Expert Opinion
25%
Nervous System Diseases
25%
Patient Selection
25%
Registry Data
25%
Literature Search
25%
Aging Population
25%
Therapeutic Targeting
25%
Immunopathology
25%
Chimera
25%
Humanized
25%
Optimal Dose
25%
Rituximab
25%
Demyelination
25%
Progressive multiple Sclerosis
25%
Risk of Malignancy
25%
Cause of Disability
25%
Long-term Safety
25%
Administration Regimen
25%
Axonal Degeneration
25%
Tumefactive multiple Sclerosis
25%
Optimal Maintenance
25%
First-line Drugs
25%
Area Cover
25%
Ocrelizumab
25%
Immunosenescence
25%
Chronic Autoimmune Diseases
25%
Disability Accumulation
25%
Ofatumumab
25%
Anti-CD20 Therapy
25%
Ublituximab
25%
First Treatment
25%
Immunology and Microbiology
Treatment of Multiple Sclerosis
100%
Multiple Sclerosis
100%
Monoclonal Antibody
100%
CD20
100%
B Cell
33%
Inflammatory Disorder
16%
Primary Progressive Multiple Sclerosis
16%
Immunosenescence
16%
Central Nervous System
16%
Immunopathology
16%
Autoimmune Disease
16%
Medline
16%
Rituximab
16%
Optimal Drug Dose
16%
Ocrelizumab
16%
Nerve Fiber Degeneration
16%
Ofatumumab
16%
Ublituximab
16%